India's Marksans Pharma up after unit gets UK approval for Vitamin B12 drug

Marksans Pharma

06/11/2023 07:52

** Shares of Marksans Pharma  MARK.NS  rise as much as 3.6%
to 116.65 rupees apiece
    ** Drug maker's unit receives marketing authorisation from
United Kingdom for Cyanocobalamin tablets
    ** Drug used to treat Vitamin B12 deficiencies and anaemia
    ** Trading volume is 2.87 mln shares as of 1:13 p.m. IST,
nearly twice the 30-day avg - LSEG data
    ** Including day's gains, MARK up 99% in 2023 so far

 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))